Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 7/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043197 | 0.93 | PTGER2 (0.51) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5043662 | 0.91 | TBXAS1 (0.51) | TBXAS1CA12CA1CA2CA4 | |
| SCHEMBL5050296 | 0.89 | PTGER2 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5046419 | 0.86 | CXCR3 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5047957 | 0.85 | CXCR3 (0.52) | TBXAS1CA12CA1CA2CA4 | |
| SCHEMBL5049404 | 0.85 | PTGER2 (0.51) | PTGER2 | |
| SCHEMBL5047934 | 0.84 | PTGER2 (0.41) | TBXAS1CA12CA1CA2CA4 | |
| SCHEMBL5043584 | 0.84 | PTGER2 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5046908 | 0.84 | CA12 (0.52) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5046352 | 0.81 | FNTA (0.45) | MEN1KMT2APTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |